Precision Testing Completed, Bolstering FDA 510(k) Submission for Fingerprint Drug Screening System
INBS is trading near its 52-week low of $1.9 (1.6% above the low) on elevated volume (2.7× avg).
Summary
Intelligent Bio Solutions completed precision testing for its fingerprint drug screening system, a key step toward FDA 510(k) clearance. Over 1,600 tests across three production runs and three independent sites confirmed consistent, reproducible results. This milestone follows the initiation of a multi-site method comparison study in June and an interference study in mid-June, building a comprehensive data package for the submission. The company is targeting the multi-billion-dollar U.S. drug screening market with its non-invasive technology. With a market cap under $5 million and shares near a 52-week low, regulatory progress is critical to the company's viability. The FDA submission timeline remains the key catalyst to watch.
At the time of this announcement, INBS was trading at $1.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $1.90 to $24.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.